Efficacy of entecavir treatment for up to 5 years in nucleos(t)ide-naïve chronic hepatitis B patients in real life

International Journal of Medical Sciences

Volumn 10, Issue 4, 2013, Pages 427-433

  Luo, Jie ^a   Li, Xiangyong ^a   Wu, Yuankai ^a   Lin, Guoli ^a   Pang, Yihua ^a   Zhang, Xiao ^a   Ao, Yunlong ^a   Du, Zhan ^b   Zhao, Zhixin ^a   Chong, Yutian ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b MEDICAL COLLEGE OF JINAN UNIVERSITY   (China)

Author keywords

Chronic; Entecavir; Hepatitis B; Nucleos(t)ide analogues; Resistance

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; NUCLEOTIDE DERIVATIVE; VIRUS DNA;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; LACTATE BLOOD LEVEL; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MYALGIA; PROBABILITY; RETROSPECTIVE STUDY; SEROCONVERSION; SIDE EFFECT; TREATMENT REFUSAL; TREATMENT RESPONSE;

CHRONIC; ENTECAVIR; HEPATITIS B; NUCLEOS(T)IDE ANALOGUES; RESISTANCE;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; FOLLOW-UP STUDIES; GUANINE; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; MUTATION; TREATMENT OUTCOME;

EID: 84874775495     PISSN: 14491907     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijms.5472     Document Type: Article

References (31)

1. Liaw YF, Kao JH, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012; 6: 531-561.
2. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. New Engl J Med. 2006; 354: 1001-1010.
3. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. New Engl J Med. 2006; 354: 1011-1020.
4. Chang TT, Chao YC, Gorbakov VV, et al. Results of up to 2 years of entecavir vs lamivudine therapy in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B. J Viral Hepat. 2009; 16: 784-789.
5. Chang TT, Lai CL, Yoon SK, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2010; 51: 422-430.
6. Yokosuka O, Takaguchi K, Fujioka S, et al. Long-term use of entecavir in nucleoside -naive Japanese patients with chronic hepatitis B infection. J Hepatol. 2010; 52: 791-799.
7. Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357: 2576-2588.
8. Liaw YF, Gane E, Leung N, et al. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology. 2009; 136: 486-495.
9. Lampertico P. Partial virological response to nucleos(t)ide analogues in naïve patients with chronic hepatitis B: From guidelines to field practice. J Hepatol. 2009; 50: 644-647.
10. Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. The Guideline of Prevention and Treatment for Chronic Hepatitis B (2010 Version). Chin J Exp Clin Infect Dis (Electronic Version). 2011; 5: 79-100.
11. Li LJ, Hou JL. Experts proposal on combination therapy of nucleos(t)ide analogues for chronic hepatitis B. Chin J Clin Infect Dis. 2011; 4: 65-68.
12. Osborn M. Safety and efficacy of entecavir for the treatment of chronic hepatitis B. Infection and Drug Resistance. 2011; 4: 55-64.
13. Wu YK, Li XY, Lin GL, et al. Comparation of the efficacy of lamivudine, adefovir dipivoxil, telbivudine and entecavir in treating NAs-naive patients with chronic HBV infection: 4-year real life data. Hepatology. 2012; 56(Suppl): 377A.
14. Yao GB, Ren H, Xu DZ, et al. Results of 3 years of continuous entecavir treatment in nucleos(t)ide-naive chronic hepatitis B patients. Zhonghua Gan Zang Bing Za Zhi. 2009; 17: 881-886.
15. Ono A, Suzuki F, Kawamura Y, et al. Long-term continuous entecavir therapy in nucleos(t)ide -naïve chronic hepatitis B patients. J Hepatol. 2012; 57: 508-514.
16. Lam YF, Yuen MF, Seto WK, et al. Current antiviral therapy of chronic hepatitis B: efficacy and Safety. Curr Hepatitis Rep. 2011; 10: 235-243.
17. Yuen MF, Seto WK, Fung J, et al. Three years of continuous entecavir therapy in treatment -naïve chronic hepatitis B patients: Viral suppression, viral resistance, and clinical safety. Am J Gastroenterol. 2011; 106: 1264-1271.
18. Zoutendijk R, Reijnders JG, Brown A, et al. Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response. Hepatology. 2011; 54: 443-451.
19. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012; 57: 167-185.
20. Chon YE, Kim SU, Lee CK, et al. Partial virological response to entecavir in treatment-naïve patients with chronic hepatitis B. Antiviral Therapy. 2011; 16: 469-477.
21. Marcellin P, Liang J. A personalized approach to optimize hepatitis B treatment in treatment -naïve patients. Antiviral therapy. 2010; 15(suppl 3): 53-59.
22. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol. 2009; 50: 227-242.
23. Keeffe EB, Zeuzem S, Koff RS, et al. Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol. 2007; 5: 890-897.
24. Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus Infection in the United States: 2008 Update. Clin Gastroenterol Hepatol. 2008; 6: 1315-1341.
25. Tenney DJ, Levine SM, Rose RE, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother. 2004; 48: 3498-3507.
26. Mirandola S, Campagnolo D, Bortoletto G, et al. Large-scale survey of naturally occurring HBV polymerase mutations associated with anti-HBV drug resistance in untreated patients with chronic hepatitis B. Journal of Viral Hepatitis. 2011; 18: e212-e216.
27. Fung SK, Mazzulli T, Sherman M, et al. Pre-existing antiviral resistance mutations among treatment naïve HBV patients can be detected by a sensitive line probe assay. J Hepatol. 2008; 48(Suppl 2): S256.
28. Fung S, Wong F, Mazzulli T, et al. Pre-existing antiviral-resistant mutation may be associated with primary non-response to lamivudine among treatment-naïve chronic hepatitis B patients. Hepatology. 2009; 50(Suppl): 523A.
29. Carrouee-Durantel S, Durantel D, Werle-Lapostolle B, et al. Suboptimal response to adefovir dipivoxil therapy for chronic hepatitis B in nucleoside-naïve patients is not due to pre-existing drug-resistant mutants. Antivir Ther. 2008; 13: 381-388.
30. Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology. 2009; 49: 1503-1514.
31. Reijnders JG, Deterding K, Petersen J, et al. Antiviral effect of entecavir in chronic hepatitis B: Influence of prior exposure to nucleos(t)ide analogues. J Hepatol. 2010; 52: 493-500.